Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings.
Our operations are strategically located in:
Lincoln, Nebraska (Corporate Headquarters)
Philadelphia, Pennsylvania
Phoenix, Arizona
Belfast, Northern Ireland,UK
Zurich, Switzerland
Vienna, Austria
Richmond, Virginia
Montreal, Quebec, Canada
For more information, visit: www.celerion.com
With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings.
Our operations are strategically located in:
Lincoln, Nebraska (Corporate Headquarters)
Philadelphia, Pennsylvania
Phoenix, Arizona
Belfast, Northern Ireland,UK
Zurich, Switzerland
Vienna, Austria
Richmond, Virginia
Montreal, Quebec, Canada
For more information, visit: www.celerion.com
Location: United States
Employees: 1001-5000
Founded date: 2010
Investors 6
| Date | Name | Website |
| - | Bain Capit... | baincapita... |
| 05.11.2022 | H.I.G. Cap... | higcapital... |
| - | H.I.G. Cap... | higprivate... |
| - | WindRose H... | windrose.c... |
| - | Court Squa... | courtsquar... |
| - | H.I.G. Cap... | hig.com/ |
Mentions in press and media 10
| Date | Title | Description |
| 24.04.2026 | Celerion: Majority Investment From THL Partners To Advance Clinical Pharmacology And Bioanalytical Innovation | Celerion, a Lincoln, Nebraska-based global leader in clinical pharmacology and bioanalytical sciences, has announced a majority investment from THL Partners, a private equity firm focused on middle-market growth companies. The investment wi... |
| 23.04.2026 | Celerion Receives Investment From THL Partners | Celerion, a Lincoln, NB-based clinical pharmacology and bioanalytical sciences company, received an investment from THL Partners. The amount of the deal was not disclosed. The company intends to use the funds to support its continued growth... |
| 05.06.2023 | AAV Vector Shedding Assay— Best Practices in Clinical Gene Therapy Method Development, Upcoming Webinar Hosted by Xtalks | A sensitive and reliable method is needed in several different matrices, usually including blood, plasma, faeces, semen, urine and saliva. TORONTO, Ontario, Canada (PRWEB) June 05, 2023 Gene therapies have demonstrated to be life-changing t... |
| 01.12.2022 | H.I.G. Capital Completes Acquisition of Celerion | MIAMI – November 3, 2022 – H.I.G. Capital (“H.I.G.”), a leading global investment firm with $52 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Celerion Holdings... |
| 21.11.2022 | Nitrosamine Impurities in Rifampin – What Does it Mean for Your Drug-Drug Interaction (DDI) Study? Upcoming Webinar Hosted by Xtalks | The speakers propose overcoming rifampin impurity challenges with the use of phenytoin for healthy volunteer pharmacokinetic drug-drug interaction studies. TORONTO (PRWEB) November 21, 2022 N-Nitrosamine impurity findings in marketed formul... |
| 22.03.2022 | Onsite Pharmacy Compounding for Your Phase 1 Clinical Study, Upcoming Webinar Hosted by Xtalks | Compliant compounding suites and on-site pharmacy activities for compounded drugs can be instrumental to the success of a drug development program. TORONTO (PRWEB) March 22, 2022 Emerging guidelines from the US Food and Drug Administration ... |
| 30.11.2021 | Clinical and Bioanalytical Aspects of Immune Monitoring via ELISpot, Upcoming Webinar Hosted by Xtalks | The FDA Bioanalytical Method Validation (BMV) guidance is not always applicable and may need to be adapted to the unique properties of ELISpot to achieve a fit-for-purpose validation. TORONTO, Ontario (PRWEB) November 30, 2021 The enzyme-li... |
| 01.06.2021 | Celerion Receives CRO Leadership Award for 6th Consecutive Year USA - English France - Français España - español Deutschland - Deutsch | |
| 10.11.2014 | The Midwest Roundup: Fundings, Deals, Exits, and Acquisitions from the Past 50 Days | Though we're hyper focused on Chicago, we're very aware of and excited about all of the innovation that's happening throughout the entire Midwest. In fact, the whole region is on track for its strongest year ever in startup investing. Every... |
| 29.10.2014 | Celerion Announces Recapitalization through Investment by MTS Health Investors | Celerion, a Lincoln, NE-based provider of clinical study solutions to pharmaceutical and biotechnology clients conducting early clinical research, has announced the successful recapitalization of its business through investment by MTS Healt... |